1189042-70-3 Usage
Uses
Used in Organic Synthesis:
2-(2-Fluoro-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is used as a reagent for the synthesis of biologically active molecules and pharmaceuticals. Its boronic ester structure allows for versatile reactions in organic chemistry, facilitating the creation of complex organic compounds with potential applications in medicine and other fields.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 2-(2-Fluoro-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is utilized as a building block for the development of new drugs. Its ability to introduce fluoro and nitro functional groups into target molecules makes it a valuable tool for medicinal chemists, who can exploit these groups to modulate the properties and activities of drug candidates.
Used in Material Science:
2-(2-Fluoro-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is also employed in the development of new materials. Its unique chemical structure and reactivity contribute to the creation of advanced materials with specific properties, such as improved stability, reactivity, or selectivity, which can be applied in various industries, including electronics, coatings, and composites.
Used in Chemical Process Development:
In the chemical process industry, 2-(2-Fluoro-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is applied as a component in the design and optimization of new chemical processes. Its reactivity and functional group versatility enable the development of more efficient and selective synthetic routes, leading to improved yields and reduced environmental impact.
Check Digit Verification of cas no
The CAS Registry Mumber 1189042-70-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,9,0,4 and 2 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1189042-70:
(9*1)+(8*1)+(7*8)+(6*9)+(5*0)+(4*4)+(3*2)+(2*7)+(1*0)=163
163 % 10 = 3
So 1189042-70-3 is a valid CAS Registry Number.
1189042-70-3Relevant articles and documents
TRICYCLIC ASK1 INHIBITORS
-
Paragraph 0520; 0521; 0576; 0577, (2019/10/29)
Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.
DIHYDROBENZOFURAN DERIVATIVES AS INSECTICIDAL COMPOUNDS
-
Page/Page column 96; 97, (2014/09/29)
Provided are compounds of formula (I) and methods of controlling insects, acarines, nematodes or molluscs, which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula (I).
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
-
Page/Page column 53, (2011/04/14)
The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABAAα2/α3 binding site agonists for the treatment of anxiety disorders
Goodacre, Simon C.,Street, Leslie J.,Hallett, David J.,Crawforth, James M.,Kelly, Sarah,Owens, Andrew P.,Blackaby, Wesley P.,Lewis, Richard T.,Stanley, Joanna,Smith, Alison J.,Ferris, Pushpinder,Sohal, Bindi,Cook, Susan M.,Pike, Andrew,Brown, Nicola,Wafford, Keith A.,Marshall, George,Castro, José L.,Atack, John R.
, p. 35 - 38 (2007/10/03)
A series of high-affinity GABAA agonists with good oral bioavailability in rat and dog and functional selectivity for the GABA Aα2 and -α3 subtypes is reported. The 7-trifluoromethylimidazopyrimidine 14g and the 7-propan-2-olimidazopyrimidine 14k are anxiolytic in both conditioned and unconditioned animal models of anxiety with minimal sedation observed at full BZ binding site occupancy.
